Ranbaxy Laboratories is currently trading at Rs. 567.20, up by 5.50 points or 0.98% from its previous closing of Rs. 561.70 on the BSE.
The scrip opened at Rs. 565.00 and has touched a high and low of Rs. 569.95 and Rs. 563.85 respectively. So far 40062 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 569.95 on 22-Jul-2014 and a 52 week low of Rs. 253.95 on 02-Aug-2013.
Last one week high and low of the scrip stood at Rs. 569.95 and Rs. 547.60 respectively. The current market cap of the company is Rs. 24050.04 crore.
The promoters holding in the company stood at 63.40% while Institutions and Non-Institutions held 20.53% and 13.65% respectively.
The two leading stock exchanges -- BSE and NSE -- have given clearance to $4-billion merger of Ranbaxy Laboratories with Sun Pharmaceutical Industries. The ‘no-objection’ from the two exchanges would allow both the entities to file their scheme of amalgamation with the High Court for further clearance of the deal and marks one of the numerous regulatory approvals that Sun Pharma and Ranbaxy need to consummate for the transaction.
The deal had separately come under scanner of the markets regulator SEBI for alleged insider trading violations and the present ‘no-objection’ from the exchanges.
The combination of Ranbaxy and Sun Pharma will create the fifth-largest speciality generics company in the world and the largest pharmaceutical company in India. The two firms now need clearances of the High Court and the Competition Commission of India (CCI), among others.
Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1661.00 |
| Dr. Reddys Lab | 1220.35 |
| Cipla | 1234.05 |
| Zydus Lifesciences | 930.95 |
| Lupin | 2307.80 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: